New Targeted Therapy with a Double-Pronged Approach

Share this content:
Antagonistic TNFR2 antibodies may offer an effective treatment for cancers positive for TNFR2.
Antagonistic TNFR2 antibodies may offer an effective treatment for cancers positive for TNFR2.

A new study is suggesting that a new targeted therapy approach may have the potential to boost antitumor immune responses and directly kill tumor cells. 

Investigators at Massachusetts General Hospital (MGH) have discovered that tumor necrosis factor receptor type II (TNFR2) may be a new target for cancer immunotherapies. TNFR2 is expressed on many types of cancer cells and on immunosuppressive regulatory T cells (Tregs) that infiltrate tumors and suppress immune system activity. The researchers report in Science Signaling on the potential of using TNFR2 antagonists as new targeted therapy.1 They write that by targeting tumor cells and immunosuppressive tumor-associated Tregs, it may be possible to use antagonistic TNFR2 antibodies as an effective treatment for cancers positive for TNFR2.

The researchers describe how it may be possible to simultaneously block an immune checkpoint molecule in T cells and an oncoprotein in tumor cells. The MGH team characterized the effects of inhibiting TNFR2 activation using antagonistic monoclonal antibodies that block rather than stimulate activation of the receptor. They demonstrated that these antibodies inhibited the proliferation of T regulatory cells, allowing a restoration of host immunity in vivo. The TNFR2 antibodies more potently killed Tregs isolated from fluid surrounding ovarian cancer metastases than Tregs from cancer-free individuals, suggesting that TNFR2-expressing Tregs are unique to the tumor microenvironment. These antagonistic antibodies also directly killed cells from a TNFR2-expressing ovarian cancer cell line.


p<1. Torrey H, Butterworth J, Mera T, et al. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal.  2017 Jan 17;10(462). doi: 10.1126/scisignal.aaf8608
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs